Sumitomo Dainippon to halve its Japanese production sites
Japanese pharma company Sumitomo Dainippon (TYO: 4506) is to reduce its four production sites in Japan to just two.
It has cited the challenges to research and development-based pharma companies, along with health care cost reduction policies as the motivation behind the reorganization. The Ibaraki plant will be integrated into the Suzuka plant by 2020, and the Ehime plant will close by 2018 through outsourcing of the products currently manufactured there.
Production will then operate from Suzuka and the company’s plant in Oita, instead of the present four sites. Employees currently working at Ibaraki and Ehime will be relocated ‘in principle’ to Suzuka.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze